selected scholarly activity
-
chapters
- The Extracellular Matrix-Cell Interaction in ILD. 126-134. 2022
- Fibrocytes in Interstitial Lung Disease. 131-141. 2011
- Growth Factors. 353-361. 2009
- Growth factors. 353-361. 2008
- Gene therapy for lung injury. 747-778. 2005
- Use of gene transfer to study lung: Cytokine biology. 171-191. 2002
-
conferences
- Effects of nintedanib on circulating biomarkers in patients with progressive pulmonary fibrosis: subgroups by fibrotic pattern on HRCT. European Respiratory Journal. 2023
- Endothelial cellular senescence contributes to the pathogenesis of IPF with pulmonary hypertension. European Respiratory Journal. 2023
- Identifying the common denominator: Dectin-1 as a promising marker for macrophage modulation in lung cancer and fibrosis. European Respiratory Journal. 2023
- Prognostic value of circulating biomarkers in patients with progressive pulmonary fibrosis. European Respiratory Journal. 2023
- Role of virtual multidisciplinary team meetings in the post-COVID era: a global survey to evaluate the ILD diagnostic pathway. European Respiratory Journal. 2023
- The clinical frailty scale is associated with progression of fibrotic interstitial lung disease – a multicentre cohort study.. European Respiratory Journal. 2023
- Win ratio approach to assessing the effect of nintedanib on a hierarchical composite endpoint in patients with progressive pulmonary fibrosis. European Respiratory Journal. 2023
- Vascular–Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling. American Journal of Respiratory and Critical Care Medicine. 1498-1514. 2023
- Associations Between L-PF Questionnaire Dyspnea Scores and Outcomes in Patients With Progressive Fibrosing ILDs: Data From the INBUILD Trial. American Journal of Respiratory and Critical Care Medicine. 2023
- Bronchoalveolar Lavage Fluid and Radiographic Patterns in Patients With Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2023
- Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Data From the INBUILD Trial. American Journal of Respiratory and Critical Care Medicine. 2023
- Clinical and Radiographic Characterization of Non-specific Interstitial Pneumonia on High-resolution CT Chest Imaging. American Journal of Respiratory and Critical Care Medicine. 2023
- Clinical and Radiographic Predictors of Mortality or Transplant in Patients With Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2023
- Computed Tomography Features Influencing Guideline-defined Radiologic Patterns In Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2023
- Dyspnea During Sexual Activity in Patients With Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2023
- Effects of Nintedanib on Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Subgroup Analyses of the INBUILD Trial. American Journal of Respiratory and Critical Care Medicine. 2023
- Generalizability of Pharmaceutical Randomized Controlled Trials for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2023
- Pathogenic Role of Extracellular Heat Shock Protein 90α (HSP90α) in Interstitial Lung Diseases Through Macrophages Programming. American Journal of Respiratory and Critical Care Medicine. 2023
- Radiologic Patterns and Leading Clinical Diagnoses in Unclassifiable Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2023
- Reprogramming Rogue Macrophages: Yeast Beta-glucan Microparticles as a Macrophage Modulator for Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2023
- Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 1156-1165. 2023
- The Clinical Frailty Scale Is Associated With Mortality in Patients With Fibrotic Interstitial Lung Disease - A Multicenter Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2023
- Neighbourhood disadvantage impacts on pulmonary function in patients with sarcoidosis. ERJ Open Research. 00357-2022. 2022
- Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis.. Respirology. 635-644. 2022
- Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest. 1594-1597. 2022
- Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest. 1320-1329. 2022
- Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulmonary Medicine. 223. 2019
- Mechanical stress-induced mast cell degranulation activates TGF-β1 signalling pathway in pulmonary fibrosis. Thorax. 455-465. 2019
- THE ROLE OF FOLLOW-UP EVALUATION IN THE DIAGNOSTIC ALGORITHM OF IDIOPATHIC INTERSTITIAL PNEUMONIA: A RETROSPECTIVE STUDY. Scientific Reports. 159-160. 2018
- CARDIOVASCULAR SAFETY OF NINTEDANIB IN SUBGROUPS BY BASELINE CARDIOVASCULAR RISK. Respirology. 101-101. 2018
- NINTEDANIB LONG-TERM EFFICACY IN IPF IS MAINTAINED IRRESPECTIVE OF DOSE. Respirology. 99-99. 2018
- M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf. Thorax. A252-+. 2017
- M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on. Thorax. A255-+. 2017
- M34 Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the tomorrow and inpulsis trials. Thorax. A255-+. 2017
- An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. Annals of the American Thoracic Society. 1239-1247. 2017
- Cardiovascular Safety Of Nintedanib In Subgroups By Cardiovascular Risk At Baseline In The Tomorrow And Inpulsis Trials. European Respiratory Journal. 2017
- Identification And Validation Of Unique And Shared M2 Macrophage Biomarkers Between Murine Models And Human Disease Using Bioinformatic Gene Expression Analysis. American Journal of Respiratory and Critical Care Medicine. 2017
- Improvement In Forced Vital Capacity (FVC) With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Results From The Inpulsis Trials. American Journal of Respiratory and Critical Care Medicine. 2017
- Long-Term Efficacy Of Nintedanib Is Maintained In Patients With Idiopathic Pulmonary Fibrosis (ipf) Irrespective Of Dose: Subgroup Analysis Of Inpulsis-On. American Journal of Respiratory and Critical Care Medicine. 2017
- Loxl1 Null Mice Are Protected From Tgf-beta 1 Induced Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2017
- Myofibroblast Rescue By Normal Extracellular Matrix. American Journal of Respiratory and Critical Care Medicine. 2017
- Nintedanib Attenuates The Polarization Of Profibrotic Macrophages Through The Inhibition Of Tyrosine Phosphorylation On Csf1 Receptor. American Journal of Respiratory and Critical Care Medicine. 2017
- Pbi-4050 Is Safe And Well Tolerated And Shows Evidence Of Benefit In Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2017
- Role Of Dendritic Cells In Pulmonary Fibrosis In Mice. American Journal of Respiratory and Critical Care Medicine. 2017
- Silica-Induced Pulmonary Fibrosis Occurs With The Activation Of Macrophage Polarization Through Marco And In A Tgf-beta 1-Independent Manner. American Journal of Respiratory and Critical Care Medicine. 2017
- The Fibrotic Extracellular Matrix (ecm) Induces Mast Cell Degranulation And Phenotypes Changing. American Journal of Respiratory and Critical Care Medicine. 2017
- The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition. American Journal of Respiratory and Critical Care Medicine. 2017
- The Roles Of Exosomal Mirna Derived From Fibrocytes In Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2017
- S98 Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatment. Thorax. A58.1-A58. 2016
- EFFECTIVE MEDICAL TREATMENT OF IPF (PIRFENIDONE AND NINTEDANIB). Respirology. 10-10. 2016
- Antiacid Therapy And Disease Progression In Patients With Idiopathic Pulmonary Fibrosis (ipf) Under Pirfenidone Treatment. American Journal of Respiratory and Critical Care Medicine. 2016
- Characterizing The Maturation Of Tgf-beta Induced Pulmonary Fibrotic Scar: Quantitation Of Extracellular Matrix Protein Synthesis, Remodeling And Crosslinking Rates. American Journal of Respiratory and Critical Care Medicine. 2016
- Effect Of Baseline Gap Index Stage On Decline In Lung Function With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf). American Journal of Respiratory and Critical Care Medicine. 2016
- How Basic Science Methodology Has Changed In The Context Of The Bleomycin Model Of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2016
- Il-6 Mediated Hyperpolarization Of Profibrotic Macrophages Is Dependent On Spliced Xbp1. American Journal of Respiratory and Critical Care Medicine. 2016
- Impact Of Statins On Lung Function Decline In Idiopathic Pulmonary Fibrosis (ipf). American Journal of Respiratory and Critical Care Medicine. 2016
- Macitentan Prevents Pulmonary Fibrosis Progression And Secondary Pulmonary Hypertension Induced By Tgf-beta 1 Overexpression In Rats. American Journal of Respiratory and Critical Care Medicine. 2016
- Pathogenesis Of Pulmonary Fibrosis - The Role Of Extracellular Heat Shock Protein-90 (hsp90) In Myofibroblast Differentiation And Persistence. American Journal of Respiratory and Critical Care Medicine. 2016
- The Value Of A Systematic Assessment Of Medication Use And Polypharmacy In Patients With Ipf. American Journal of Respiratory and Critical Care Medicine. 2016
- EFFECT OF BASELINE FVC ON DECLINE IN LUNG FUNCTION WITH NINTEDANIB IN PATIENTS WITH IPF: RESULTS FROM THE INPULSIS (R) TRIALS. Respirology. 84-84. 2015
- S108 Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials. Thorax. A62.1-A62. 2015
- Camk Ii And Tgf beta-Mediated Extracellular Matrix Gene Expression In Human Pulmonary Fibroblasts. American Journal of Respiratory and Critical Care Medicine. 2015
- Effect Of Baseline FVC On Decline In Lung Function With Nintedanib In Patients With Ipf: Results From The Inpulsis (R) Trials. American Journal of Respiratory and Critical Care Medicine. 2015
- Fibroblast Growth Factor-1 Attenuates Tgf-beta 1-Induced Lung Fibrosis By Regulating Tgf-beta 1 Signaling. American Journal of Respiratory and Critical Care Medicine. 2015
- Involvement Of Adenylate Cyclase Pathway In Regulating Calcium Signaling In Human Pulmonary Fibroblasts. American Journal of Respiratory and Critical Care Medicine. 2015
- Mechanical Stress And Mast Cell Activation On Tgf-beta 1 Induced Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2015
- Pathogenesis Of Pulmonary Fibrosis: The Role Of Extracellular Heat Shock Protein-90 (hsp90) In Myofibroblast Differentiation And Persistence. American Journal of Respiratory and Critical Care Medicine. 2015
- Prevalence And Incidence Of Idiopathic Pulmonary Fibrosis In Canada. American Journal of Respiratory and Critical Care Medicine. 2015
- Smad3 And Ttf-1 Complexes Regulate Surfactant Dysfunction During Overexpression Of Tgf-beta 1 And Contribute To Loss Of Epithelial Integrity In Vivo. American Journal of Respiratory and Critical Care Medicine. 2015
- Streptococcus Pneumoniae Triggers Progression Of Pulmonary Fibrosis Through Pneumolysin. American Journal of Respiratory and Critical Care Medicine. 2015
- The Etiology Of Idiopathic Interstitial Pneumonias (iip) In Chinese Patients: A Single Center Serial Cases Analysis. American Journal of Respiratory and Critical Care Medicine. 2015
- Transplantation Of Cd117+Cells Derived From The Lungs Of Rats With Severe Pulmonary Hypertension Induce Pulmonary Vascular And Alveolar Remodeling. American Journal of Respiratory and Critical Care Medicine. 2015
- EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: RESULTS OF TWO 52-WEEK, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (INPULSIS (TM)). Respirology. 28-28. 2014
- Prevalence And Incidence Of Interstitial Pulmonary Diseases With Fibrosis. Value in Health. A171-A171. 2014
- Ca2+-Waves And Ca2+/calmodulin-Dependent Protein Kinase Ii (camk Ii) beta And delta Activation Are Involved In Transforming Growth Factor beta (tgf beta)-Mediated Gene Transcription Of Matrix Genes. American Journal of Respiratory and Critical Care Medicine. 2014
- Efficacy And Safety Of Nintedanib In Patients With Idiopathic Pulmonary Fibrosis: Results Of Two 52-Week, Phase Iii, Randomized, Placebo-Controlled Trials (inpulsis (TM)). American Journal of Respiratory and Critical Care Medicine. 2014
- Fibroblast Growth Factor-1 Attenuates Tgf beta 1-Induced Lung Fibrosis Through Inhibition Of Smad2 Phosphorylation. American Journal of Respiratory and Critical Care Medicine. 2014
- Fkbp13 Deficiency Leads To Increased Pulmonary Er Stress, Inflammation And Fibrosis After Bleomycin Administration. American Journal of Respiratory and Critical Care Medicine. 2014
- Grp78 Heterozygosity Abrogates Bleomycin-Induced Lung Fibrosis By Modulating Er-Resident Protein Folding Capacity. American Journal of Respiratory and Critical Care Medicine. 2014
- Identification Of A Novel Region Of The Itgb6 Promoter Responsible For Basal Repression Of Itgb6 Transcription And Therefore av beta 6 Expression. American Journal of Respiratory and Critical Care Medicine. 2014
- Inhaled Pirfenidone Improves Animal Efficacy Through Superior Pulmonary And Vascular Pharmacokinetics. American Journal of Respiratory and Critical Care Medicine. 2014
- Nifedipine Attenuates Bleomycin-Induced Fibrosis By Blocking Calcium Wave Activity. American Journal of Respiratory and Critical Care Medicine. 2014
- Prostaglandin E2 Inhibits Calcium Signaling In Normal And Ipf Pulmonary Fibroblasts. American Journal of Respiratory and Critical Care Medicine. 2014
- The Kinetics Of Crosslinking Enzymes And Ecm Components In Experimental Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2014
- Transfer Of Active Tgf-beta 1 To The Mouse Lung: Early Effects On Lung Mechanics, Structure And Surfactant Function In Vivo. American Journal of Respiratory and Critical Care Medicine. 2014
- Interdependence of HIF1 alpha/TGF beta 1 activity in induction of pulmonary fibrosis. European Respiratory Journal. 2013
- Mechanisms regulating enhanced alpha v beta 6 expression in pulmonary fibrosis. European Respiratory Journal. 2013
- Mechanisms regulating enhanced alpha v beta 6 expression in pulmonary fibrosis. European Respiratory Journal. 2013
- 4-Phenylbutyrate Prevents Upr Activation And Myofibroblast Differentiation In Experimental Bleomycin-Induced Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2013
- Ca2+Waves Are Necessary And Sufficient For Transforming Growth Factor Beta Mediated Gene Expression In Human Pulmonary Fibroblasts. American Journal of Respiratory and Critical Care Medicine. 2013
- Fibroblast Growth Factor-1 Ameliorates Tgf-beta 1-Induced Lung Dysfunction And Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2013
- Modifying Fibrocyte Responses In Rat Bleomycin-Induced Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2013
- Multiple Mechanisms Regulating Enhanced Expression Of alpha v beta 6 Integrins In Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2013
- Experimental Lung Fibrosis and Pulmonary Hypertension Induces Cardiomyocyte Apoptosis and Right Ventricular Dysfunction. Circulation. 2011
- Adenoviral Gene Transfer Of Granulocyte/Macrophage Colony Stimulating Factor Enhances Pulmonary Host Defense And Survival From Pneumococcal Pneumonia In Mice. American Journal of Respiratory and Critical Care Medicine. 2011
- The effect of curcumin in transforming growth factor beta 1-induced rat lung fibrosis. The FASEB Journal. 2011
- Latent TGF Activated By Mechanical Force Promotes Endogenous TGF Positive Feedback. American Journal of Respiratory and Critical Care Medicine. 2011
- The Effect Of Interleukin-13 Induced Goblet Cell Metaplasia On Airway Barrier Function. American Journal of Respiratory and Critical Care Medicine. 2011
- Tissue Repair In Cystic Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine. 2011
- Transforming Growth Factor Beta (TGF-beta) Evoked Ca2+Wave And Enhanced Gene Expression In Cultured Human Pulmonary Fibroblast. American Journal of Respiratory and Critical Care Medicine. 2011
- Transient Adenovirus-mediated Overexpression Of HIF-1± Induces Epithelial Injury In Rat Lungs. American Journal of Respiratory and Critical Care Medicine. 2010
- Gene Transfer Of Extracellular Superoxide Dismutase Ameliorates Pulmonary Fibrosis In Rats. American Journal of Respiratory and Critical Care Medicine. 2010
- VEGF receptor inhibition in experimental lung fibrosis results in severe angioproliferative pulmonary hypertension and increased fibrogenic activity. American Journal of Respiratory and Critical Care Medicine. 2010
- Effects of Bacterial Infection withPseudomonas aeruginosaon Experimental Pulmonary Fibrosis.. American Journal of Respiratory and Critical Care Medicine. 2009
- TGF-beta Antagonist Antibody 1D11 Blocks Experimental Progressive Pulmonary Fibrosis.. American Journal of Respiratory and Critical Care Medicine. 2009
- VEGF Overexpression during Fibrogenesis Reduces Endothelial Cell Apoptosis and Improves Pulmonary Hypertension.. American Journal of Respiratory and Critical Care Medicine. 2009
- ATP-evoked Ca2±waves Stimulate Gene Expression In Human Airway Fibroblasts. Biophysical Journal. 559a-559a. 2009
- ATP-Evoked Ca2+-Waves Stimulate Expression of Matrix Genes in Human Lung Fibroblasts.. American Journal of Respiratory and Critical Care Medicine. 2009
- BMP-Antagonist Gremlin Induces Fibroblastic Foci through EMT in the Rodent Lung. American Journal of Respiratory and Critical Care Medicine. 2009
- Mechanical Stimulation of Fibrotic Ex Vivo Lung Strips Activates Latent TGF beta. American Journal of Respiratory and Critical Care Medicine. 2009
- Transforming Growth Factor-β: Importance in Long-Term Peritoneal Membrane Changes. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 15-17. 2005
- Irradiation-induced proliferation of lung fibroblasts in co-culture.. American Journal of Respiratory and Critical Care Medicine. A195-A195. 1999
-
journal articles
- Modulating pro-fibrotic macrophages using yeast beta-glucan microparticles prepared by Pressurized Gas eXpanded liquid (PGX) Technology®.. Clinical Materials. 313:122816. 2025
- Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis.. The Lancet Respiratory Medicine. 12:848-851. 2024
- A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease.. BMC Pulmonary Medicine. 24:547. 2024
- Epidemiology and Prognostic Significance of Cough in Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 210:1035-1044. 2024
- Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response. Rheumatology. 63:2734-2740. 2024
- Worsening dyspnoea as a predictor of progression of pulmonary fibrosis.. European Respiratory Journal. 64:2302211. 2024
- Innate T-cell-derived IL-17A/F protects from bleomycin-induced acute lung injury but not bleomycin or adenoviral TGF-β1-induced lung fibrosis in mice.. European Journal of Immunology. e2451323. 2024
- Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine. American Journal of Respiratory and Critical Care Medicine. 210:401-423. 2024
- The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. American Journal of Respiratory and Critical Care Medicine. 210:392-400. 2024
- Organic Exposures, Radiologic Features, and Patterns in Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 21:1216-1218. 2024
- CD206+macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis. Thorax. thorax-2023-221168. 2024
- Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi‐centre registry cohort. Respirology. 29:596-604. 2024
- Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 21:1007-1014. 2024
- Repetitive invasive lung function maneuvers do not accentuate experimental fibrosis in mice. Scientific Reports. 14:13774. 2024
- Defective mesenchymal Bmpr1a-mediated BMP signaling causes congenital pulmonary cysts. eLife. 12:RP91876. 2024
- Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis. Chest. 165:1435-1443. 2024
- Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. European Respiratory Review. 33:240015-240015. 2024
- Exploring alveolar recruitability using positive end-expiratory pressure in mice overexpressing TGF-β1: a structure–function analysis. Scientific Reports. 14:8080. 2024
- Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials. Expert Opinion on Emerging Drugs. 29:177-186. 2024
- Characteristics of pulse oximetry and arterial blood gas in patients with fibrotic interstitial lung disease. BMJ Open Respiratory Research. 11:e002250-e002250. 2024
- Sex and Racial Differences in Lung Biopsies for Interstitial Lung Diseases in Canada. Annals of the American Thoracic Society. 21:516-519. 2024
- Examining the incidence of interstitial lung disease subtypes in South America. Jornal de Pneumologia. 50:e20240028-e20240028. 2024
- Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report. American Journal of Respiratory and Critical Care Medicine. 209:362-373. 2024
- The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung Disease. Chest. 166:517-527. 2024
- Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 209:137-152. 2024
- Characteristics and risk factors of interstitial pneumonia with autoimmune features. Respiratory Medicine. 221:107500-107500. 2024
- Publishing the pandemic: the impact of COVID-19 on science and scientific publishing. ERS Monograph. 2024:295-299. 2024
- Therapeutic strategies to target connective tissue growth factor in fibrotic lung diseases. Pharmacology and Therapeutics. 253:108578-108578. 2024
- Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics. Advances in Therapy. 40:5536-5546. 2023
- Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest. 164:1466-1475. 2023
- Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 20:1726-1734. 2023
- Reply to: Huang et al.. American Journal of Respiratory and Critical Care Medicine. 208:1242-1243. 2023
- Leukocyte telomere length: the dawn of a new era of personalised medicine in fibrotic interstitial lung diseases?. European Respiratory Journal. 62:2301852-2301852. 2023
- Defective mesenchymal Bmpr1a-mediated BMP signaling causes congenital pulmonary cysts. bioRxiv. 4:2023.09.26.559527. 2023
- Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial. Clinical Rheumatology. 42:2311-2319. 2023
- Reporting Standards for Diagnostic Testing. Journal of Bronchology. 30:207-222. 2023
- The endothelium in lung fibrosis: a core signaling hub in disease pathogenesis?. American Journal of Physiology - Cell Physiology. 325:C2-C16. 2023
- A roadmap for developing and engineering in vitro pulmonary fibrosis models. Biophys Rev (Melville). 4:021302. 2023
- Endothelial cells in pulmonary fibrosis: more than a bystander. European Respiratory Journal. 61:2300407-2300407. 2023
- A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity. European Respiratory Journal. 61:2300653-2300653. 2023
- Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. European Respiratory Journal. 61:2202163-2202163. 2023
- Intrinsic BMP inhibitor Gremlin regulates alveolar epithelial type II cell proliferation and differentiation. Biochemical and Biophysical Research Communications. 656:53-62. 2023
-
Myeloid‐specific deletion of activating transcription factor 6 alpha increases
CD11b + macrophage subpopulations and aggravates lung fibrosis. Immunology and Cell Biology. 101:412-427. 2023 -
Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the
INBUILD trial. Respirology. 28:465-474. 2023 - Therapeutic strategies targeting pro-fibrotic macrophages in interstitial lung disease. Biochemical Pharmacology. 211:115501-115501. 2023
- Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort. Journal of Thoracic Disease. 15:2517-2527. 2023
- Emerging drugs in the treatment of chronic cough. Expert Opinion on Emerging Drugs. 28:67-77. 2023
- Another piece in the pirfenidone puzzle. European Respiratory Journal. 61:2300240-2300240. 2023
- Design considerations and implications of findings on progressive pulmonary fibrosis from the prospective Canadian Registry for Pulmonary Fibrosis. European Respiratory Journal. 61:2300208-2300208. 2023
- Idiopathic pulmonary fibrosis: state of the art for 2023. European Respiratory Journal. 61:2200957-2200957. 2023
- Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. European Respiratory Review. 32:220206-220206. 2023
- Progressive pulmonary fibrosis: an expert group consensus statement. European Respiratory Journal. 61:2103187-2103187. 2023
- Nintedanib in chILD: a small step, yes… but at least a step forward in a marathon!. European Respiratory Journal. 61:2201797-2201797. 2023
- Trajectories and Prognostic Significance of 6-Minute Walk Test Parameters in Fibrotic Interstitial Lung Disease. Chest. 163:345-357. 2023
- Mapping EQ5D utilities from forced vital capacity and diffusing capacity in fibrotic interstitial lung disease. PLoS ONE. 18:e0283110-e0283110. 2023
- Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. American Journal of Respiratory and Critical Care Medicine. 207:102-105. 2023
- Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis. European Respiratory Journal. 61:2202261-2202261. 2023
- Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Respiratory Medicine. 11:87-96. 2023
- Association of Particulate Matter Exposure With Lung Function and Mortality Among Patients With Fibrotic Interstitial Lung Disease. JAMA Internal Medicine. 182:1248-1248. 2022
- Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respiratory Research. 23:54. 2022
- Lung cancer in pulmonary fibrosis: no room for nihilism!. European Respiratory Journal. 60:2201946-2201946. 2022
- Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax. 77:1243-1250. 2022
- Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice. Respiratory Research. 23:180. 2022
- Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse. American Journal of Respiratory and Critical Care Medicine. 206:1294-1295. 2022
- Clinical relevance of rheumatoid factor and anti‐citrullinated peptides in fibrotic interstitial lung disease. Respirology. 27:854-862. 2022
- Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal. 60:2102571-2102571. 2022
- The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. Advances in Therapy. 39:3881-3895. 2022
- Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial. Journal of Experimental and Clinical Cancer Research. 41:255. 2022
- FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology. 67:173-187. 2022
- Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine. 206:247-259. 2022
- Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society. 19:962-970. 2022
- Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial). American Journal of Respiratory and Critical Care Medicine. 205:1084-1092. 2022
- Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 19:863-867. 2022
- Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine. 195:106792-106792. 2022
- Heterogeneous manifestation of pulmonary ossification in idiopathic pulmonary fibrosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 6:121-125. 2022
- B Cells Are Not Involved in the Regulation of Adenoviral TGF-β1– or Bleomycin-Induced Lung Fibrosis in Mice. Journal of Immunology. 208:1259-1271. 2022
- Connective-Tissue Growth Factor Contributes to TGF-β1–induced Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 66:260-270. 2022
- Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal. 59:2004538-2004538. 2022
- Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 205:459-467. 2022
- Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI insight. 7:e155655. 2022
- Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest. 161:470-482. 2022
- Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine. 191:106722-106722. 2022
- R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life. European Respiratory Journal. 59:2100917-2100917. 2022
- The CaT stretcher: An open-source system for delivering uniaxial strain to cells and tissues (CaT). Frontiers in Bioengineering and Biotechnology. 10:959335. 2022
- The evolution of the European Respiratory Journal: adapting in an era of change. European Respiratory Journal. 59:2200037-2200037. 2022
- Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society. 19:20-27. 2022
- Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research. 22:84. 2021
- Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research. 22:202. 2021
- Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications. Expert Opinion on Therapeutic Targets. 25:939-948. 2021
- Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society. 18:1661-1668. 2021
- Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax. 76:895-906. 2021
- Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. Journal of Rheumatology. 48:1427-1434. 2021
- The justification for the progressive fibrotic phenotype. Current Opinion in Pulmonary Medicine. 27:363-367. 2021
- Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. International Journal of Molecular Sciences. 22:9316-9316. 2021
- Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis. European Respiratory Journal. 58:2100172-2100172. 2021
- Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. Respirology. 26:683-689. 2021
- A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture. Cells. 10:1538-1538. 2021
- Abrogation of mesenchyme-specific TGF-β signaling results in lung malformation with prenatal pulmonary cysts in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology. 320:L1158-L1168. 2021
- Inhaled Treprostinil in Group 3 Pulmonary Hypertension. New England Journal of Medicine. 384:1869-1872. 2021
- Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution?. European Respiratory Journal. 57:2100691-2100691. 2021
- Guideline-directed management of COVID-19: Do's and Don'ts. European Respiratory Journal. 57:2100753-2100753. 2021
- Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 5:93-96. 2021
- Role of the COX2-PGE2 axis in S. pneumoniae-induced exacerbation of experimental fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology. 320:L377-L392. 2021
- FK506-Binding Protein 13 Expression Is Upregulated in Interstitial Lung Disease and Correlated with Clinical Severity. A Potentially Protective Role. American Journal of Respiratory Cell and Molecular Biology. 64:235-246. 2021
- The case of methotrexate and the lung: Dr Jekyll and Mr Hyde. European Respiratory Journal. 57:2100079-2100079. 2021
- HSP47: a potential target for fibrotic diseases and implications for therapy. Expert Opinion on Therapeutic Targets. 25:49-62. 2021
- 3D Bioprinting Strategies, Challenges, and Opportunities to Model the Lung Tissue Microenvironment and Its Function. Frontiers in Bioengineering and Biotechnology. 9:773511. 2021
- Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Therapeutic Advances in Pulmonary and Critical Care Medicine. 15:117954842110060-117954842110060. 2021
- Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine. 8:699644. 2021
- Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 76:37-43. 2021
- Mouse Models of Lung Fibrosis. Methods in molecular biology (Clifton, N.J.). 2299:291-321. 2021
- The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal. 57:2100084-2100084. 2021
- A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research. 21:322. 2020
- Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine. 20:3. 2020
- Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest. 158:2270-2274. 2020
- Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. European Respiratory Journal. 56:2003147-2003147. 2020
- Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:226-228. 2020
- Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:214-225. 2020
- Guidance production before evidence generation for critical issues: the example of COVID-19. European Respiratory Review. 29:200310-200310. 2020
- Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease. Annals of the American Thoracic Society. 17:1077-1084. 2020
- Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest. 158:1069-1078. 2020
- Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current Opinion in Pulmonary Medicine. 26:436-442. 2020
- Current models of pulmonary fibrosis for future drug discovery efforts. European Journal of Sport Science. 15:931-941. 2020
- Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship. Pulmonary Pharmacology and Therapeutics. 63:101933-101933. 2020
- Sputum quantitative cytometry in patients with interstitial lung disease and chronic cough. Respiratory Medicine. 170:106067-106067. 2020
- Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:147-155. 2020
- TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signalling. European Respiratory Journal. 55:1901346-1901346. 2020
- The cardiovascular system in idiopathic pulmonary fibrosis. ERS Monograph. 2020:198-211. 2020
- The importance of interventional timing in the bleomycin model of pulmonary fibrosis. European Respiratory Journal. 55:1901105-1901105. 2020
- Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine. 8:453-460. 2020
- Regulatory T Cells Limit Pneumococcus-Induced Exacerbation of Lung Fibrosis in Mice. Journal of Immunology. 204:2429-2438. 2020
- Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal. 55:1901760-1901760. 2020
- Making the case for causality: what role do lung microbiota play in idiopathic pulmonary fibrosis?. European Respiratory Journal. 55:2000318-2000318. 2020
- Prognostic impact of typical and probable usual interstitial pneumonia pattern in idiopathic pulmonary fibrosis: is the debate about biopsy a Star Wars saga?. European Respiratory Journal. 55:2000590-2000590. 2020
- Multidisciplinary team approach on a case of bilateral interstitial pneumonia. Journal of Xiangya Medicine. 5:1-1. 2020
- Clonally selected primitive endothelial cells promote occlusive pulmonary arteriopathy and severe pulmonary hypertension in rats exposed to chronic hypoxia. Scientific Reports. 10:1136. 2020
- Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 4:25-30. 2020
- The evolution of the European Respiratory Journal: ready for the new decade!. European Respiratory Journal. 55:1902503-1902503. 2020
- Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine. 200:1505-1512. 2019
- Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. Expert Review of Respiratory Medicine. 13:1139-1146. 2019
- A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator. Journal of Thoracic Disease. 11:5547-5556. 2019
- The natural history of progressive fibrosing interstitial lung diseases. Respiratory Research. 20:57. 2019
- Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest. 156:887-895. 2019
- Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 200:1146-1153. 2019
- Fibrocytes and fibroblasts—Where are we now. International Journal of Biochemistry and Cell Biology. 116:105595-105595. 2019
- The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy. 36:3279-3287. 2019
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine. 381:1718-1727. 2019
- The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis. Thorax. 74:947-957. 2019
- What have we learned from basic science studies on idiopathic pulmonary fibrosis?. European Respiratory Review. 28:190029-190029. 2019
- Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respiratory Medicine. 156:20-25. 2019
- Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal. 54:1900161-1900161. 2019
- Surfactant dysfunction and alveolar collapse are linked with fibrotic septal wall remodeling in the TGF-β1-induced mouse model of pulmonary fibrosis. Laboratory Investigation. 99:830-852. 2019
- Molecular breath analysis for IPF: Can we make a few breaths count?. Respirology. 24:404-405. 2019
- The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study. Scientific Reports. 9:6452. 2019
- Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research. 5:00127-2018. 2019
- The characterisation of interstitial lung disease multidisciplinary team meetings: a global study. ERJ Open Research. 5:00209-2018. 2019
- Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. European Respiratory Journal. 53:1801655-1801655. 2019
- Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 53:1800663-1800663. 2019
- Pulmonary fibrosis: “idiopathic” is not “cryptogenic”. European Respiratory Journal. 53:1900400-1900400. 2019
-
IL ‐6 mediatesER expansion during hyperpolarization of alternatively activated macrophages. Immunology and Cell Biology. 97:203-217. 2019 - Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?. European Respiratory Journal. 53:1801939-1801939. 2019
- The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators of Inflammation. 2019:1-10. 2019
- Therapeutic targets and early stage clinical trials for pulmonary fibrosis. Expert Opinion on Investigational Drugs. 28:19-28. 2019
- Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society. 16:22-28. 2019
- The evolution of theEuropean Respiratory Journal: volume 2. European Respiratory Journal. 53:1802459-1802459. 2019
- Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review. 27:180071-180071. 2018
- Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 379:1722-1731. 2018
- Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2:234-243. 2018
- Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2:257-258. 2018
- Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension. European Respiratory Journal. 52:1701857-1701857. 2018
- Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?. European Respiratory Journal. 52:1801321-1801321. 2018
- Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 52:1702593-1702593. 2018
- Matrix abnormalities in pulmonary fibrosis. European Respiratory Review. 27:180033-180033. 2018
- Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP. Pneumologie. 72:446-457. 2018
- Thoracoscopic surgery for tracheal and carinal resection and reconstruction under spontaneous ventilation. Journal of Thoracic and Cardiovascular Surgery. 155:2746-2754. 2018
- Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal. 51:1702133-1702133. 2018
- What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal. 51:1800692-1800692. 2018
- Lysyl Oxidase–Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-β1–induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 58:461-470. 2018
- Identification of periplakin as a major regulator of lung injury and repair in mice. JCI insight. 3:90163. 2018
- Adenoviral vector-mediated GM-CSF gene transfer improves anti-mycobacterial immunity in mice – role of regulatory T cells. Immunobiology. 223:331-341. 2018
- Idiopathic pulmonary fibrosis: idiopathic no more?. The Lancet Respiratory Medicine. 6:84-85. 2018
- Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. European Respiratory Journal. 51:1700386-1700386. 2018
- A Switch in TGF-β Signaling Explains Contradictory Findings in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 197:157-159. 2018
- Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research. Volume 10:127-137. 2018
- New advances in the development of sarcoidosis models: a synopsis of a symposium sponsored by the Foundation for Sarcoidosis Research.. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 35:2-4. 2018
- Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration; international review of thoracic diseases. 95:317-326. 2018
- The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. European Respiratory Journal. 51:1702420-1702420. 2018
- Turning thirty: evolution but not revolution at the ERJ. European Respiratory Journal. 51:1702594-1702594. 2018
- Palliative care in interstitial lung disease: living well. The Lancet Respiratory Medicine. 5:968-980. 2017
- Personalised medicine for IPF: getting closer, but not there yet. The Lancet Respiratory Medicine. 5:836-837. 2017
- Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis. Scientific Reports. 7:13281. 2017
- Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine. 131:49-57. 2017
- Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society. 14:1373-1377. 2017
- Silent minority: argument, information sharing, and polarization of minority opinion through a structuration theory lens. Journal of Applied Communication Research. 45:381-396. 2017
- Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study. European Respiratory Journal. 50:1700936-1700936. 2017
- Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 1:133-141. 2017
- A female patient with recurrent lung lesion and hilar lymphadenopathy. Journal of Thoracic Disease. 9:1858-1863. 2017
- Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. European Respiratory Journal. 49:1700811-1700811. 2017
- An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 56:667-679. 2017
- Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 72:340-346. 2017
- Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax. 72:148-153. 2017
- Heat shock protein: a hot topic in idiopathic pulmonary fibrosis. European Respiratory Journal. 49:1602152-1602152. 2017
- Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration; international review of thoracic diseases. 93:415-423. 2017
- M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner. Journal of Leukocyte Biology. 101:285-295. 2017
- A 43-year-old man with cough, expectoration and recurrent wheezing. Journal of Thoracic Disease. 8:3468-3477. 2016
- Pathways to Precision Medicine in Idiopathic Pulmonary Fibrosis. Time to Relax?. American Journal of Respiratory and Critical Care Medicine. 194:1315-1317. 2016
- The Language of Extremity. Journal of Language and Social Psychology. 35:603-627. 2016
- Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. European Respiratory Journal. 48:1524-1526. 2016
- Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis. Journal of Pathology. 240:197-210. 2016
- First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung. 194:739-743. 2016
- Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply. The Lancet Respiratory Medicine. 4:e48-e48. 2016
- High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society. 13:1640-1647. 2016
- Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine. 194:265-275. 2016
- GRP78 and CHOP modulate macrophage apoptosis and the development of bleomycin-induced pulmonary fibrosis. Journal of Pathology. 239:411-425. 2016
- Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. European Respiratory Journal. 48:187-195. 2016
- Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury. Stem Cell Research. 17:25-31. 2016
- Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 194:84-96. 2016
- Surfactant dysfunction during overexpression of TGF-β1 precedes profibrotic lung remodeling in vivo. American Journal of Physiology - Lung Cellular and Molecular Physiology. 310:L1260-L1271. 2016
- Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. European Respiratory Journal. 47:1776-1784. 2016
- Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. The Lancet Respiratory Medicine. 4:381-389. 2016
- Editorial: Extracellular Matrix: The Common Thread of Disease Progression in Fibrosis?. Arthritis & Rheumatology. 68:1053-1056. 2016
- Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. Thorax. 71:399-400. 2016
- An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. American Journal of Respiratory and Critical Care Medicine. 193:792-800. 2016
- Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 193:355-357. 2016
- Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis. PLoS ONE. 11:e0158047-e0158047. 2016
- Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE. 11:e0151425-e0151425. 2016
- Interstitial lung disease: time to rethink the snapshot diagnosis?. Thorax. 71:5-7. 2016
- Other comorbidities. ERS Monograph. 2016:186-195. 2016
- The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal. 2016:1-7. 2016
- Deception, Detection, Demeanor, and Truth Bias in Face-to-Face and Computer-Mediated Communication. Communication Research. 42:1116-1142. 2015
- Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Medicine. 13:176. 2015
- The CAnadian REgistry for Pulmonary Fibrosis (CARE-PF): Design and rationale of a national pulmonary fibrosis registry.. Canadian Respiratory Journal. 17206. 2015
- Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. American Journal of Respiratory Cell and Molecular Biology. 53:450-458. 2015
- Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology. 20:1010-1022. 2015
- A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal. 46:243-249. 2015
-
A novel profibrotic mechanism mediated by
TGFβ ‐stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. Journal of Pathology. 236:384-394. 2015 - Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax. 70:636-646. 2015
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal. 45:1434-1445. 2015
- Antifibrotic Role of αB-Crystallin Inhibition in Pleural and Subpleural Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 52:244-252. 2015
- Drug development for chronic lung disease ‐ Mission impossible?. Respirology. 20:13-14. 2015
- Rapid detection of circulating fibrocytes by flowcytometry in idiopathic pulmonary fibrosis. Annals of Thoracic Medicine. 10:279-279. 2015
- Fibrocytes and Progression of Fibrotic Lung Disease. Ready for Showtime?. American Journal of Respiratory and Critical Care Medicine. 190:1338-1339. 2014
- Influenza Promotes Collagen Deposition via αvβ6 Integrin-mediated Transforming Growth Factor β Activation. Journal of Biological Chemistry. 289:35246-35263. 2014
- miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology. 53:432-441. 2014
- Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respiratory Medicine. 108:1023-1030. 2014
- Staging of idiopathic pulmonary fibrosis: past, present and future. European Respiratory Review. 23:220-224. 2014
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 370:2071-2082. 2014
- Glycosyltransferases and Glycosaminoglycans in Bleomycin and Transforming Growth Factor-β1–Induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 50:583-594. 2014
-
The small heat‐shock protein α
B ‐crystallin is essential for the nuclear localization of Smad4: impact on pulmonary fibrosis. Journal of Pathology. 232:458-472. 2014 - Cardiopulmonary Exercise Testing to Detect Chronic Thromboembolic Pulmonary Hypertension in Patients with Normal Echocardiography. Respiration; international review of thoracic diseases. 87:379-387. 2014
- Pulmonary and Cardiac Function in Asymptomatic Obese Subjects and Changes following a Structured Weight Reduction Program: A Prospective Observational Study. PLoS ONE. 9:e107480-e107480. 2014
- Fibrocytes in pulmonary fibrosis: a brief synopsis. European Respiratory Review. 22:552-557. 2013
- New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. Expert Review of Respiratory Medicine. 7:465-478. 2013
- Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. Current Opinion in Pulmonary Medicine. 19:446-452. 2013
- Inflammation and dysregulated fibroblast proliferation--new mechanisms?. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 30 Suppl 1:21-26. 2013
- Lung surgery in interstitial lung disease-a safe and useful procedure?. Journal of Thoracic Disease. 5:375-377. 2013
- Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. European Respiratory Journal. 42:230-238. 2013
- Platelet derived growth factor-evoked Ca2+ wave and matrix gene expression through phospholipase C in human pulmonary fibroblast. International Journal of Biochemistry and Cell Biology. 45:1516-1524. 2013
- Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. The FASEB Journal. 27:1549-1560. 2013
- Idiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side. Respiration; international review of thoracic diseases. 86:441-452. 2013
- Vascular Repair and Regeneration as a Therapeutic Target for Pulmonary Arterial Hypertension. Respiration; international review of thoracic diseases. 85:355-364. 2013
- Identification of RARRES1 as a core regulator in liver fibrosis. Journal of Molecular Medicine. 90:1439-1447. 2012
- Fibrocytes in chronic lung disease – Facts and controversies. Pulmonary Pharmacology and Therapeutics. 25:263-267. 2012
- Molecular mechanisms of MMP9 overexpression and its role in emphysema pathogenesis of Smad3-deficient mice. American Journal of Physiology - Lung Cellular and Molecular Physiology. 303:L89-L96. 2012
- Angiogenesis in Pulmonary Fibrosis. Chest. 142:200-207. 2012
- Transforming Growth Factor–β Evokes Ca2+ Waves and Enhances Gene Expression in Human Pulmonary Fibroblasts. American Journal of Respiratory Cell and Molecular Biology. 46:757-764. 2012
- Adenovirus-Mediated Gene Transfer of TGF-β1 to the Renal Glomeruli Leads to Proteinuria. American Journal of Pathology. 180:940-951. 2012
- Local Delivery of GM-CSF Protects Mice from Lethal Pneumococcal Pneumonia. Journal of Immunology. 187:5346-5356. 2011
- Pulmonary Microcirculation in Interstitial Lung Disease. Annals of the American Thoracic Society. 8:516-521. 2011
- Cigarette smoke exposure aggravates air space enlargement and alveolar cell apoptosis inSmad3knockout mice. American Journal of Physiology - Lung Cellular and Molecular Physiology. 301:L391-L401. 2011
- Idiopathic Pulmonary Fibrosis: The Matrix Is the Message. American Journal of Respiratory and Critical Care Medicine. 184:627-629. 2011
- In VivoRole of Platelet-Derived Growth Factor–BB in Airway Smooth Muscle Proliferation in Mouse Lung. American Journal of Respiratory Cell and Molecular Biology. 45:566-572. 2011
- Oxidative stress contributes to the induction and persistence of TGF-β1 induced pulmonary fibrosis. International Journal of Biochemistry and Cell Biology. 43:1122-1133. 2011
- Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 45:1-15. 2011
- Viruses and Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 183:1583-1584. 2011
- Transient Overexpression of Gremlin Results in Epithelial Activation and Reversible Fibrosis in Rat Lungs. American Journal of Respiratory Cell and Molecular Biology. 44:870-878. 2011
- Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of β1,3-glucuronosyltransferase I in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology. 300:L191-L203. 2011
- Renal tubular angiogenic dysregulation in anti-Thy1.1 glomerulonephritis. American Journal of Physiology - Renal Physiology. 300:F488-F498. 2011
- The promise of electronic data capture in respiratory medicine. European Respiratory Journal. 37:228-230. 2011
- Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-β1. Respiratory Research. 11:181. 2010
- Overexpression of transforming growth factor- 1 in fetal monkey lung results in prenatal pulmonary fibrosis. European Respiratory Journal. 36:907-914. 2010
- Have advanced research technologies made real impact on respiratory medicine?. Respirology. 15:876-880. 2010
- Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.. IDrugs: the Investigational Drugs Journal. 13:332-345. 2010
- Management of idiopathic pulmonary fibrosis. Minerva Pneumologica. 49:73-82. 2010
- Platelet derived growth factor B and epithelial mesenchymal transition of peritoneal mesothelial cells. Matrix Biology. 29:97-106. 2010
- Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney International. 77:319-328. 2010
- Bleomycin induces pleural and subpleural fibrosis in the presence of carbon particles. European Respiratory Journal. 35:176-185. 2010
- Identification of Fibrocytes in Peripheral Blood. American Journal of Respiratory and Critical Care Medicine. 180:1279-1280. 2009
- ATP stimulates Ca2+-waves and gene expression in cultured human pulmonary fibroblasts. International Journal of Biochemistry and Cell Biology. 41:2477-2484. 2009
- How useful is traditional herbal medicine for pulmonary fibrosis?. Respirology. 14:1082-1091. 2009
- Treating IPF—all or nothing? A PRO‐CON debate. Respirology. 14:1072-1081. 2009
- Update on models of pulmonary fibrosis therapy for preclinical drug research. Expert Opinion on Drug Discovery. 4:939-946. 2009
- Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology. 174:1683-1691. 2009
- VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. Journal of Clinical Investigation. 119:1298-1311. 2009
- Respirology year‐in‐review 2008: Basic science. Respirology. 14:318-326. 2009
- Circulating Fibrocytes Are an Indicator of Poor Prognosis in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 179:588-594. 2009
- Role of STAT6 and SMAD2 in a model of chronic allergen exposure: a mouse strain comparison study. Clinical and Experimental Allergy. 39:147-158. 2009
- Comparison between conventional and "clinical" assessment of experimental lung fibrosis. Journal of Translational Medicine. 6:16. 2008
- TGF- receptor II in epithelia versus mesenchyme plays distinct roles in the developing lung. European Respiratory Journal. 32:285-295. 2008
- An Official ATS Conference Proceedings: Advances in Small-Animal Imaging Application to Lung Pathophysiology. Annals of the American Thoracic Society. 5:591-600. 2008
- Targeting fibrosis in respiratory lung disease. Drug Discovery Today: Therapeutic Strategies. 5:97-100. 2008
- The use of small animal imaging in respiratory disease drug discovery. Drug Discovery Today: Therapeutic Strategies. 5:81-85. 2008
- Animal models of pulmonary fibrosis: how far from effective reality?. American Journal of Physiology - Lung Cellular and Molecular Physiology. 294:L151-L151. 2008
- Progressive pulmonary fibrosis is mediated by TGF-β isoform 1 but not TGF-β3. International Journal of Biochemistry and Cell Biology. 40:484-495. 2008
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. International Journal of Biochemistry and Cell Biology. 40:362-382. 2008
- Three-dimensional computed tomography imaging in an animal model of emphysema. European Respiratory Journal. 30:1082-1089. 2007
- TGF-β1 Induces Progressive Pleural Scarring and Subpleural Fibrosis. Journal of Immunology. 179:6043-6051. 2007
- TGF-β, Smad3 and the process of progressive fibrosis. Biochemical Society Transactions. 35:661-664. 2007
- TGFβ and Smad3 link inflammation to progressive fibrosis. International Congress Series. 1302:103-113. 2007
- Gene therapy for cystic fibrosis. Multidisciplinary Respiratory Medicine. 2:72-77. 2007
- Smad3 Signaling Involved in Pulmonary Fibrosis and Emphysema. Annals of the American Thoracic Society. 3:696-702. 2006
- Gene Therapy for Pulmonary Diseases. Chest. 130:879-884. 2006
- Models of pulmonary fibrosis. Drug Discovery Today: Disease Models. 3:243-249. 2006
- Strategies targeting fibrosis in pulmonary disease. Drug Discovery Today: Therapeutic Strategies. 3:389-394. 2006
- Targeting Genes for Treatment in Idiopathic Pulmonary Fibrosis: Challenges and Opportunities, Promises and Pitfalls. Annals of the American Thoracic Society. 3:389-393. 2006
- The transforming growth factor-beta (TGF-β) family and pulmonary fibrosis. Drug Discovery Today: Disease Mechanisms. 3:99-103. 2006
- TGF-β and Smad3 Signaling Link Inflammation to Chronic Fibrogenesis. Journal of Immunology. 175:5390-5395. 2005
- Progressive Transforming Growth Factor β1–induced Lung Fibrosis Is Blocked by an Orally Active ALK5 Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine. 171:889-898. 2005
- Connective Tissue Growth Factor Is Crucial to Inducing a Profibrotic Environment in “Fibrosis-Resistant” Balb/c Mouse Lungs. American Journal of Respiratory Cell and Molecular Biology. 31:510-516. 2004
- Smad3 Null Mice Develop Airspace Enlargement and Are Resistant to TGF-β-Mediated Pulmonary Fibrosis. Journal of Immunology. 173:2099-2108. 2004
- Bioterrorismus und Lunge. Deutsche Medizinische Wochenschrift. 129:93-96. 2004
- Adenoviral Gene Transfer of Connective Tissue Growth Factor in the Lung Induces Transient Fibrosis. American Journal of Respiratory and Critical Care Medicine. 168:770-778. 2003
- Transdiaphragmatic liver herniation mimicking pulmonary nodule. European Journal of Radiology Extra. 46:17-20. 2003
- Pathogenese der idiopathischen Lungenfibrose. Atemwegs- und Lungenkrankheiten. 29:99-102. 2003
- Die Bedeutung von Zytokinen und Wachstumsfaktoren bei fibrosierenden Lungenerkrankungen. Pneumologie. 57:91-97. 2003
- Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis. Current Pharmaceutical Design. 9:39-49. 2003
- Fatal Pericardial Tamponade After Wallstent Implantation for Malignant Superior Vena Cava Syndrome. Journal of Endovascular Therapy. 9:680-684. 2002
- Differences in the Fibrogenic Response after Transfer of Active Transforming Growth Factor-β1 Gene to Lungs of “Fibrosis-prone” and “Fibrosis-resistant” Mouse Strains. American Journal of Respiratory Cell and Molecular Biology. 27:141-150. 2002
- Inflammatory Cytokines, Angiogenesis, and Fibrosis in the Rat Peritoneum. American Journal of Pathology. 160:2285-2294. 2002
- Antiangiogenic and Antifibrotic Gene Therapy in a Chronic Infusion Model of Peritoneal Dialysis in Rats. Journal of the American Society of Nephrology. 13:721-728. 2002
- A new direction in the pathogenesis of idiopathic pulmonary fibrosis?. Respiratory Research. 3:1. 2002
- A Chronic Inflammatory Infusion Model of Peritoneal Dialysis in Rats. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 21:368-372. 2001
- Gene Transfer of Transforming Growth Factor-β1 to the Rat Peritoneum. Journal of the American Society of Nephrology. 12:2029-2039. 2001
- Budesonide Enhances Repeated Gene Transfer and Expression in the Lung with Adenoviral Vectors. American Journal of Respiratory and Critical Care Medicine. 164:866-872. 2001
- Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. Journal of Clinical Investigation. 107:1529-1536. 2001
- Proteoglycans decorin and biglycan differentially modulate TGF-β-mediated fibrotic responses in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology. 280:L1327-L1334. 2001
- Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin. American Journal of Respiratory and Critical Care Medicine. 163:770-777. 2001
- Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. American Journal of Respiratory and Critical Care Medicine. 163:770-777. 2001
- Unerwünschte (kardio-)vaskuläre Wirkungen von Vinorelbin beim nichtkleinzelligen Bronchialkarzinom1. Pneumologie. 54:54-57. 2000
- [Autocrine activation of fibroblasts following irradiation].. Pneumologie. 53:296-301. 1999
- Tumor markers in serum and in the bronchoalveolar lavage fluid. Atemwegs- und Lungenkrankheiten. 25:24-32. 1999
- Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. European Respiratory Journal. 12:1409-1414. 1998
- Immunosuppressive therapy of idiopathic pulmonary fibrosis with cyclophosphamide. Atemwegs- und Lungenkrankheiten. 24:554-559. 1998
- Determinants of coronary effects of atrial natriuretic factor in dogs. European Journal of Clinical Investigation. 22:516-522. 1992